
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Mission: Early cancer detection via fragmentomics-based, ML analysis of cell-free DNA from blood
Founded: 2019
Lead product / tech: DELFI-TF (genome-wide cfDNA fragmentation analysis with machine learning)
Notable financing: $225M Series B (July 18, 2022); total funding reported ~$330.5M
Headcount (approx.): 176 employees
Early cancer detection and treatment monitoring using liquid biopsy (fragmentomics of cell-free DNA).
2019
Biotechnology Research
$225,000,000
Announced Series B to develop portfolio of liquid biopsy tests
“Participation from strategic and institutional investors including Eli Lilly, Point72, Brown Advisory, Menlo Ventures, OrbiMed, Samsara BioCapital, T. Rowe Price, and others”
| Company |
|---|
About Us
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible, and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
Lead with Science, Anchor in Pragmatism : We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
Build With & For All : We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
Put We over I : We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
About the Role
Join our innovative team dedicated to reducing cancer deaths through cutting-edge liquid biopsy diagnostics. As Sr. Research Associate, you will play a critical role in developing and validating next-generation sequencing assays from concept through commercial launch, working within a collaborative environment of scientists, engineers, and bioinformaticians. You will contribute to product development, verification, and validation activities for NGS-based laboratory tests for early cancer detection. The ideal candidates would have experience working under Good Laboratory Practice (GLP) in a CAP/CLIA/FDA-regulated environment.
What you’ll do
What you’ll have accomplished 6 months from now
What you’ll bring to DELFI
Preferred qualifications :
An equal opportunity employerWe are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.